# Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

> **NCT00601094** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** autologous dendritic cell-adenovirus CCL21 vaccine

## Key facts

- **NCT ID:** NCT00601094
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-26
- **Primary completion:** 2017-05-23
- **Final completion:** 2017-05-23
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00601094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00601094, "Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00601094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*